Case Study: Phage Enrichment
Phage display is a powerful toolkit for antibody discovery and engineering. In this study, we used phage display to identify Cas9-binding single domain (VHH) antibodies. In addition to traditional colony picking, we used our Reptor immune repertoire sequencing platform to monitor the phage panning process and identify additional hits that were not found in the traditional workflow.
Reptor is a proprietary antibody repertoire analysis workflow to enable deep interrogation of the immune response and antibody discovery processes. In this project, we used Reptor to analyze B cells from peripheral blood of an immunized llama as well as a phage library generated from the same bleeds.
A llama was immunized with Cas9 and peripheral blood mononuclear cells (PBMCs) were collected. A VHH library was constructed from the PBMCs. The library went through 3 rounds of selection against the immunogen, Cas9. DNA was extracted from an aliquot of the pre-panned library (R0), and after each round of selection (R1, R2, and R3).
From the final R3 library, 88 transformants were found to be binders to the target, which after sequencing revealed 26 unique clones as defined by CDR3 sequence. These clones make up the ‘panning hits’.
In addition, Reptor was used to sequence the pre-panned library as well as the R1, R2, and R3 libraries. Enrichment analysis was performed to identify library sequences that increased in abundance between R0 and R3. These hits make up the ‘NGS hits’.
Finally, from the same PBMC samples used to create the phage library, Reptor constructed an antibody repertoire for the heavy chain only isotypes (IgG2B and IgG2C). This repertoire was used for hit expansion (‘PBMC repertoire’).
PBMC versus Phage Repertoire Analysis: We used Reptor to compare the PBMC repertoire derived from PBMCs to the phage library repertoire. The PBMC repertoire contained 478,828 CDR3s, while the phage library (combining R0, R1, R2, R3) contained 169,447 clones. The majority of the clones found across all phage libraries (66%) are present in the R0 library, which is more diverse than any of the post-panning libraries. There is little overlap between the CDR3s found in the two repertoires with 44,066 of 604,209 (~7%) CDR3s shared between the phage libraries and the PBMC repertoire.
Phage Enrichment Analysis: In total 1,512 antibodies were identified in all panning rounds. From these, the enrichment score after each panning round versus the pre-panned library were calculated and plotted.
A plot of enrichment of clones after each round of panning (1, 2, or 3) versus the pre-panned library. The red highlighted lines are the 12 VHHs selected for testing.
Binding analysis: From the 25 sequences with final enrichment score of at least 2.5 between R3 and R0, 12 with the highest enrichment slopes were selected for testing. Of the 12 NGS hits tested, all 12 showed binding to the target in ELISA. The 12 NGS hits had distinct CDR3s from the panning hits. Among the 26 panning hits tested, 24 expressed but only 6 showed binding to the target.
Hit expansion: All 12 of the NGS hits have relatives in the PBMC-derived repertoires. Reptor revealed between 2 and 78 sequences that share the same CDR3 as the NGS hits.
A lineage tree of sequences from the PBMC-derived repertoire that share CDR3 and germline V gene with one of the NGS hits. Red and orange nodes are sequences derived from early bleeds while yellow and green nodes are sequences derived from late bleeds. The two blue nodes are from the NGS hits.
Reptor uses hit expansion to find related hits with different characteristics from the primary hit. For example, in the lineage above, 3 of the sequences contain N-glycan motifs in the CDR2. Hit expansion identifies alternate sequences with identical CDR3 but without the N-glycan motif.
- Reptor analysis of phage libraries reveals novel clones that are enriched across panning, but not identified due to undersampling at end.
- NGS enables hit expansion, with all enrichment hits having relatives the remnant PBMCs.
New Service: Alicanto for Antibody Discovery from Human SerumWe recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were...
Having a diverse collection of leads at the beginning of your antibody development campaign is critical for downstream success. As we know well, the immune response to immunization often focuses on a small number of antibody families with highly similar CDR3s which...
Abterra Biosciences is a unique CRO offering antibody sequencing and discovery services. We bring sophisticated algorithmic and machine learning approaches to enable accurate antibody sequencing and functional antibody discovery.
Tell Us About Your Project
Follow Abterra Bio On Social Media
More From Our Blog
Abterra Opens Its Doors To Celebrate New Location With Open HouseCelebrating milestones is an...
New Service: Alicanto for Antibody Discovery from Human SerumWe recently had the pleasure of...
Abterra Bio Has Moved To Sorrento Valley In 2009, Abterra Bio began as Digital Proteomics LLC, a...